SBIO
ALPS Medical Breakthroughs ETF
Price Chart
Latest Quote
$55.48
+1.70 (+3.16%)
Current Price
| Previous Close | $53.78 |
| Open | $53.68 |
| Day High | $55.48 |
| Day Low | $53.52 |
| Volume | 39,499 |
Fund Information
| Net Assets | $211.56M |
| Expense Ratio | 0.50% |
| Category | Health |
| Fund Family | ALPS |
| Net Asset Value | $53.72 |
| Premium/Discount | 3.27% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $54.13 |
| SMA50 | $60.66 |
| SMA200 | $56.98 |
| RSI | 54.10 |
| ATR | 1.6621 |
| Rel Volume | 1.03 |
Performance History
| Week | +1.22% |
| Month | -4.23% |
| Quarter | -12.13% |
| 6 Months | +3.62% |
| YTD | +10.61% |
| Year | +30.59% |
| 3 Years | +135.92% |
| 5 Years | +26.76% |
| 10 Years | +171.22% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $55.48 | 39,499 |
| 2026-10-26 | $53.78 | 36,200 |
| 2026-10-23 | $53.38 | 58,400 |
| 2026-10-22 | $54.55 | 13,900 |
| 2026-10-21 | $54.57 | 19,300 |
| 2026-10-20 | $54.81 | 22,900 |
| 2026-10-19 | $52.11 | 20,100 |
| 2026-10-16 | $50.12 | 20,700 |
| 2026-10-15 | $52.22 | 35,800 |
| 2026-10-14 | $51.20 | 33,700 |
| 2026-10-13 | $51.64 | 33,300 |
| 2026-10-12 | $53.85 | 22,700 |
| 2026-10-09 | $55.04 | 33,600 |
| 2026-10-08 | $53.94 | 53,300 |
| 2026-10-07 | $54.13 | 49,200 |
| 2026-10-06 | $54.38 | 93,200 |
| 2026-10-05 | $56.26 | 52,300 |
| 2026-10-02 | $56.15 | 59,500 |
| 2026-10-01 | $56.64 | 43,700 |
| 2026-09-30 | $58.30 | 22,000 |
| 2026-09-29 | $57.94 | 26,800 |
| 2026-09-28 | $57.93 | 29,700 |
About ALPS Medical Breakthroughs ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
đ° Latest News
No news articles available at the moment. Check back later for updates on SBIO.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.